Deciphering the Reversible Cardiotoxicity of Osimertinib: The Role of the GATA4-MYLK3-MYL2 Axis

MedXY Editorial Team•Jan 3, 2026•Clinical Updates

Osimertinib-induced contractile dysfunction is characterized by significant reversibility upon treatment cessation and an absence of classical markers of permanent damage such as cardiomyocyte death, inflammation, or fibrosis.
The mechanism of cardiotoxicity involves the suppression of the GATA4-MYLK3-MYL2 signaling axis, leading to reduced MYL2 phosphorylation and subsequent sarcomere disarray.
Transcriptional downregulation of MYLK3 is driven by the dephosphorylation of the transcription factor GATA4, which is identified as a primary putative target of osimertinib in the heart.
The myosin activator omecamtiv represents a potential pharmacological strategy to prevent or rescue cardiac dysfunction associated with third-generation EGFR inhibitors.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Osimertinib-induced contractile dysfunction is characterized by significant reversibility upon treatment cessation and an absence of classical markers of permanent damage such as cardiomyocyte death, inflammation, or fibrosis.
The mechanism of cardiotoxicity involves the suppression of the GATA4-MYLK3-MYL2 signaling axis, leading to reduced MYL2 phosphorylation and subsequent sarcomere disarray.
Transcriptional downregulation of MYLK3 is driven by the dephosphorylation of the transcription factor GATA4, which is identified as a primary putative target of osimertinib in the heart.
The myosin activator omecamtiv represents a potential pharmacological strategy to prevent or rescue cardiac dysfunction associated with third-generation EGFR inhibitors.